mhurhangee/ep-ind-claims huggingface dataset:
A method for printing on a substrate by means of inkjet printing, in which method - landing zones are specified on the substrate and - the landing zones are each printed with an individual pattern consisting of at least two droplets by means of print head nozzles of at least one print head, wherein - the print head nozzles and the surface of the substrate are moved relative to one another during printing, characterized in that - the printing of the droplets within at least a part of the individual patterns, preferably within each of the individual patterns, is performed such that mutual influence of the droplets within an individual pattern on the substrate is counteracted. - landing zones are specified on the substrate and - the landing zones are each printed with an individual pattern consisting of at least two droplets by means of print head nozzles of at least one print head, wherein - the print head nozzles and the surface of the substrate are moved relative to one another during printing, - the printing of the droplets within at least a part of the individual patterns, preferably within each of the individual patterns, is performed such that mutual influence of the droplets within an individual pattern on the substrate is counteracted.
A mammalian or yeast host cell engineered to express: (i) at least one nucleic acid encoding a fusion polypeptide having β(1,4)-N-acetylglucosaminyltransferase III (GnT III) activity and at least one nucleic acid encoding a polypeptide having mannosidase II (Man II) activity; or (ii) at least one nucleic acid encoding a fusion polypeptide having GnT III activity, at least one nucleic acid encoding a polypeptide having Man II activity and at least one nucleic acid encoding a polypeptide having β(1,2)-N-acetylglucosaminyltransferase II (GnT II) activity; wherein the host cell is engineered to express said nucleic acids in an amount sufficient to modify the oligosaccharides in the Fc region of a polypeptide produced by said host cell, wherein said polypeptide produced by said host cell is selected from the group consisting of a whole antibody molecule, an antibody fragment retaining a functional Fc region, and a fusion protein that includes a region equivalent to the Fc region of an immunoglobin, wherein said fusion polypeptide having GnT III activity comprises the Golgi localization domain of a heterologous Golgi resident polypeptide, and wherein said mammalian host cell is a cultured cell, or comprised within cultured animal tissue, or comprised within a transgenic non-human animal. (i) at least one nucleic acid encoding a fusion polypeptide having β(1,4)-N-acetylglucosaminyltransferase III (GnT III) activity and at least one nucleic acid encoding a polypeptide having mannosidase II (Man II) activity; or (ii) at least one nucleic acid encoding a fusion polypeptide having GnT III activity, at least one nucleic acid encoding a polypeptide having Man II activity and at least one nucleic acid encoding a polypeptide having β(1,2)-N-acetylglucosaminyltransferase II (GnT II) activity; wherein the host cell is engineered to express said nucleic acids in an amount sufficient to modify the oligosaccharides in the Fc region of a polypeptide produced by said host cell, wherein said polypeptide produced by said host cell is selected from the group consisting of a whole antibody molecule, an antibody fragment retaining a functional Fc region, and a fusion protein that includes a region equivalent to the Fc region of an immunoglobin, wherein said fusion polypeptide having GnT III activity comprises the Golgi localization domain of a heterologous Golgi resident polypeptide, and wherein said mammalian host cell is a cultured cell, or comprised within cultured animal tissue, or comprised within a transgenic non-human animal.
A bone filling composite comprising: a bone filler comprising: microparticles of at least one elastomeric material comprising a poly(glycerol sebacate)-based thermoset; and a filler dopant in the at least one elastomeric material; and a carrier material mixed with the bone filler, the carrier material comprising: a poly(glycerol sebacate) resin; and at least one carrier dopant. microparticles of at least one elastomeric material comprising a poly(glycerol sebacate)-based thermoset; and a filler dopant in the at least one elastomeric material; and a carrier material mixed with the bone filler, the carrier material comprising: a poly(glycerol sebacate) resin; and at least one carrier dopant. a poly(glycerol sebacate) resin; and at least one carrier dopant.
Device for overcoming an obstacle which has two sides (4, 5), in particular a step and/or door threshold, wherein the device consists of a base element, a supporting body, a movement apparatus and a drive, and the supporting body can be moved by means of the drive between an inoperative position and a functional position in a rotational manner about an edge, which is averted from the obstacle, and in a translatory manner, in particular in a horizontal manner, in the direction of the obstacle, and the device has a position securing means, wherein the movement apparatus is fastened to the base element and to the supporting body by means of articulated joints, characterized in that the movement apparatus has a connection for the drive, and the drive comprises a movement converter which has a track-like recess in which the connection is arranged in a movable manner.
A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human Eg5 gene in a cell, wherein said dsRNA comprises at least two sequences that are complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence comprising a region of complementarity which is fully complementary to at least a part of a mRNA encoding Eg5, wherein said region of complementarity is less than 30 nucleotides in length, wherein said part of a mRNA encoding Eg5 consists of the sequence UCGAGAAUCUAAACUAACU, and wherein said dsRNA, upon contact with a cell expressing said Eg5, inhibits expression of said Eg5 gene.
An image forming apparatus comprising: an image forming section configured to perform image formation on a sheet; a body housing formed by a box body with a flat top surface and configured to contain the image forming section; a protruding housing protruding upward from the flat top surface, the protruding housing having an upward slope rising from the front side to the back side and a top portion formed by a convex surface; a light diffusing portion disposed in the protruding housing; a light source located inside the body housing or the protruding housing and configured to emit light; a light guide configured to guide light emitted by the light source to the light diffusing portion; and a control unit configured to control illumination of the light source based on information related to the image formation, the light diffusing portion being formed by a transparent member having a light diffusing surface for diffusing the light outwardly, characterized in that the top portion is in the highest position in the image forming apparatus, the protruding housing has a groove, the groove formed by a recessed part of the top portion, and the light diffusing portion is positioned inside the groove. an image forming section configured to perform image formation on a sheet; a body housing formed by a box body with a flat top surface and configured to contain the image forming section; a protruding housing protruding upward from the flat top surface, the protruding housing having an upward slope rising from the front side to the back side and a top portion formed by a convex surface; a light diffusing portion disposed in the protruding housing; a light source located inside the body housing or the protruding housing and configured to emit light; a light guide configured to guide light emitted by the light source to the light diffusing portion; and a control unit configured to control illumination of the light source based on information related to the image formation, the light diffusing portion being formed by a transparent member having a light diffusing surface for diffusing the light outwardly, characterized in that the top portion is in the highest position in the image forming apparatus, the protruding housing has a groove, the groove formed by a recessed part of the top portion, and the light diffusing portion is positioned inside the groove.
A method to prepare a coated current collector electrode for a flow through capacitor, the method comprising: a preparing a coating paste comprising by weight %: 10 - 50 weight % of carbon having a specific surface area of at least 500 m2/g; 0.3 - 5 weight % of a binder; 10 - 50 weight % based on the total paste of a first solvent having a first boiling point; and, 10 - 50 weight % based on the total paste of a second solvent having a second boiling point; the second boiling point being lower than the first boiling point b applying the coating paste onto a current collector; and, c allowing the second solvent in the coating paste applied on the current collector to evaporate at a temperature lower than the first boiling point, wherein the first solvent is a polyol. a preparing a coating paste comprising by weight %: 10 - 50 weight % of carbon having a specific surface area of at least 500 m2/g; 0.3 - 5 weight % of a binder; 10 - 50 weight % based on the total paste of a first solvent having a first boiling point; and, 10 - 50 weight % based on the total paste of a second solvent having a second boiling point; the second boiling point being lower than the first boiling point 10 - 50 weight % of carbon having a specific surface area of at least 500 m2/g; 0.3 - 5 weight % of a binder; 10 - 50 weight % based on the total paste of a first solvent having a first boiling point; and, 10 - 50 weight % based on the total paste of a second solvent having a second boiling point; the second boiling point being lower than the first boiling point b applying the coating paste onto a current collector; and, c allowing the second solvent in the coating paste applied on the current collector to evaporate at a temperature lower than the first boiling point, wherein the first solvent is a polyol.
Lamp operating device comprising a control input (D 1, D 2), wherein there are at least two dimming levels (DS_OFF. DS_ON) stored in the lamp operating device, wherein a first dimming level corresponds to an quiescent value (DS_OFF) and a second dimming level corresponds to an desired operational value (DS_ON) of a lamp, and wherein one of the dimming levels is selectively activated by a motion detector as a function of a control signal which is applied to the control input (D 1, D 2), characterized in that there are at least two dimming scenarios stored in the lamp operating device, each of which is characterized by the value of at least one dimming parameter which represents the transition between the quiescent value (DS_OFF) and the desired operational value (DS_ON), or between the desired operational value (DS_ON) and the quiescent value (DS_OFF), wherein the least two dimming scenarios differ by the respective value of the at least one dimming parameter, and wherein the lamp operating device is configured to statistically evaluate the control signal received by the motion sensor and to select one of the at least two dimming scenarios as a function of the evaluation.
A method for pre-treating lithium metal for a lithium secondary battery comprising: a stripping step of removing the surface oxide film formed on the lithium metal by discharging the battery, and a plating step of replenishing lithium metal on the lithium metal, from which the surface oxide film has been removed by the stripping step, by charging the battery, wherein the stripping step is performed by discharging the battery 1 time to 13 times at a current density of 5 to 20 mA/cm 2 for a time period of 20 to 120 seconds each, and wherein the plating step is performed by charging the battery 1 time to 13 times at a current density of 0.01 to 0.2 mA/cm 2 for a time period of 1,000 to 7,000 seconds each. a stripping step of removing the surface oxide film formed on the lithium metal by discharging the battery, and a plating step of replenishing lithium metal on the lithium metal, from which the surface oxide film has been removed by the stripping step, by charging the battery, wherein the stripping step is performed by discharging the battery 1 time to 13 times at a current density of 5 to 20 mA/cm 2 for a time period of 20 to 120 seconds each, and wherein the plating step is performed by charging the battery 1 time to 13 times at a current density of 0.01 to 0.2 mA/cm 2 for a time period of 1,000 to 7,000 seconds each.
A method of improving the European Production Efficiency Factor (EPEF) and/or feed conversion ratio of a monogastric animal comprising administering an animal feed or animal feed additive comprising one or more microbial lysozymes to the monogastric animal wherein the microbial lysozyme is obtained or obtainable from the kingdom Fungi and is administered at a level of 8 to 250 ppm enzyme protein per kg animal feed, wherein the microbial lysozyme is selected from the group consisting of: a) a polypeptide having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 4; (b) a variant of SEQ ID NO: 4 wherein the variant has lysozyme activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 positions; and (c) a fragment of the polypeptide of (a) or (b) that has lysozyme activity wherein the fragment comprises at least 210 amino acids, such as at least 215 amino acids, at least 220 amino acids, at least 225 amino acids, at least 230 amino acids, at least 235 amino acids or at least 240 amino acids; wherein the monogastric animal is selected from the group consisting of swine, piglet, growing pig, sow, poultry, turkey, duck, quail, guinea fowl, goose, pigeon, squab, chicken, broiler, layer, pullet and chick. a) a polypeptide having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 4; (b) a variant of SEQ ID NO: 4 wherein the variant has lysozyme activity and comprises one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 positions; and (c) a fragment of the polypeptide of (a) or (b) that has lysozyme activity wherein the fragment comprises at least 210 amino acids, such as at least 215 amino acids, at least 220 amino acids, at least 225 amino acids, at least 230 amino acids, at least 235 amino acids or at least 240 amino acids;
A stent for the controlled release of at least one first and one second active principle for treating the stent implantation site, wherein: - the at least one first and one second active principle are different from each other and are selected from anti-proliferative drugs and anti-inflammatory drugs, respectively, - the at least one first and one second active principle are loaded on at least one portion of the stent surface in a layered configuration comprising at least one first and one second layer, wherein: - the first layer is created on the at least one portion of the stent surface and comprises the at least one first active principle and at least one or more first excipients, and - the second layer is created on the first layer and comprises the at least one second active principle and at least one or more second excipients, wherein said at least one or more first excipients are selected from fatty acids having a linear or branched saturated chain comprising a number of carbon atoms between 16 and 34, and said at least one or more second excipients are selected from fatty acids having a linear or branched saturated chain comprising a number of carbon atoms between 4 and 18, and wherein said at least one or more first excipients or a mixture thereof has/have a melting temperature greater than the melting temperature of said at least one or more second excipients or a mixture thereof. - the at least one first and one second active principle are different from each other and are selected from anti-proliferative drugs and anti-inflammatory drugs, respectively, - the at least one first and one second active principle are loaded on at least one portion of the stent surface in a layered configuration comprising at least one first and one second layer, wherein: - the first layer is created on the at least one portion of the stent surface and comprises the at least one first active principle and at least one or more first excipients, and - the second layer is created on the first layer and comprises the at least one second active principle and at least one or more second excipients,
Apparatus for eliciting a blood sample, the apparatus comprising; a testing member (208, 505) rotatably mounted on a shaft; and an aperture for positioning a body part of the user relative to the edge of the testing member, wherein an edge of the testing member is shaped such as repeatedly to exert pressure on the skin of a user when the testing member is rotated.
Ultrasonic motor, comprising: - an actuator in the form of a piezo-electric plate with two main surfaces having the largest areas and at least four side surfaces (19, 20) connecting the main surfaces with one another, wherein at least one friction element is arranged on at least one of the side surfaces; - an element to be driven which is in active contact with the friction element of the actuator and is driven via the same; - a tensioning device for pressing the at least one friction element against the element to be driven; - and a thermo-compensation platform having abutting sections against which the associated side surfaces of the actuator abut so that a displacement of the actuator is only possible along the abutting side surfaces, characterized in that the tensioning device comprises two rotation angle levers, wherein each rotation angle lever comprises one tension lever arm and one pressure lever arm, and wherein the two tension lever arms are connected to one another via a tensioned tension spring, and the tensile force of the tension spring exerts a torque on the rotation angle lever in such a way that each of the pressure lever arms acts with a defined force on that side surface of the actuator which is opposite to the side surface on which the at least one friction element is arranged so that the actuator is pressed along the abutting sections and linearly guided by them in the direction of the element to be driven. - an actuator in the form of a piezo-electric plate with two main surfaces having the largest areas and at least four side surfaces (19, 20) connecting the main surfaces with one another, wherein at least one friction element is arranged on at least one of the side surfaces; - an element to be driven which is in active contact with the friction element of the actuator and is driven via the same; - a tensioning device for pressing the at least one friction element against the element to be driven; - and a thermo-compensation platform having abutting sections against which the associated side surfaces of the actuator abut so that a displacement of the actuator is only possible along the abutting side surfaces, characterized in that the tensioning device comprises two rotation angle levers, wherein each rotation angle lever comprises one tension lever arm and one pressure lever arm, and wherein the two tension lever arms are connected to one another via a tensioned tension spring, and the tensile force of the tension spring exerts a torque on the rotation angle lever in such a way that each of the pressure lever arms acts with a defined force on that side surface of the actuator which is opposite to the side surface on which the at least one friction element is arranged so that the actuator is pressed along the abutting sections and linearly guided by them in the direction of the element to be driven.
A process for producing cholesterol from fish oil, in which said fish oil has a certain amount of anthropogenic contaminants, comprising the following steps: (a) distilling fish oil in an admixture with an auxiliary fluid comprising one or more fatty acid ethyl ester composed of C10-C22 fatty acids in a vacuum distillation column conducted at an evaporation temperature of 150 to 300°C and a column pressure of 0.0001 to 0.5 mbar to obtain a first residue and a first distillate, (b) distilling the first distillate in a vacuum distillation column conducted at an evaporation temperature of 100 to 250°C and a column pressure of 0.0001 to 0.5 mbar to obtain a second distillate and a second residue, (c) contacting the second residue with an alkali metal hydroxide to produce a saponified mixture, (d) contacting the saponified mixture with a non-polar organic solvent or a mixture of non-polar organic solvents to produce an organic phase and an aqueous phase, (e) separating the organic phase from the aqueous phase, (f) cooling the organic phase to form a solid phase and a liquid phase, and (g) separating the solid phase from the organic phase, wherein the separated solid phase comprises cholesterol comprising at least 95 wt.% of cholesterol and having a lower content of anthropogenic contaminants than in the fish oil, wherein the cholesterol is formed in a single extraction-crystallization step. (a) distilling fish oil in an admixture with an auxiliary fluid comprising one or more fatty acid ethyl ester composed of C10-C22 fatty acids in a vacuum distillation column conducted at an evaporation temperature of 150 to 300°C and a column pressure of 0.0001 to 0.5 mbar to obtain a first residue and a first distillate, (b) distilling the first distillate in a vacuum distillation column conducted at an evaporation temperature of 100 to 250°C and a column pressure of 0.0001 to 0.5 mbar to obtain a second distillate and a second residue, (c) contacting the second residue with an alkali metal hydroxide to produce a saponified mixture, (d) contacting the saponified mixture with a non-polar organic solvent or a mixture of non-polar organic solvents to produce an organic phase and an aqueous phase, (e) separating the organic phase from the aqueous phase, (f) cooling the organic phase to form a solid phase and a liquid phase, and (g) separating the solid phase from the organic phase, wherein the separated solid phase comprises cholesterol comprising at least 95 wt.% of cholesterol and having a lower content of anthropogenic contaminants than in the fish oil, wherein the cholesterol is formed in a single extraction-crystallization step.
A compound of formula: wherein X 1 is O or NH; X 2 is O or NH; X 3 is O or NH; R 1 and R 2 each independently represents -H, -C1-C22 alkyl, -C1-C22 (hydroxy)alkyl, -C1-C22 (amino)alkyl or -C3-C22 alkenyl, or a pharmaceutically acceptable salt thereof. X 1 is O or NH; X 2 is O or NH; X 3 is O or NH; R 1 and R 2 each independently represents -H, -C1-C22 alkyl, -C1-C22 (hydroxy)alkyl, -C1-C22 (amino)alkyl or -C3-C22 alkenyl, or a pharmaceutically acceptable salt thereof.